In conclusion, the study suggests ONC‐212 may represent an effective treatment for high risk CLL disease by inhibiting multiple facets of the BCR signaling pathway and the pro‐survival effects of the BCL2‐family proteins. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.